SAN DIEGO, Oct. 13, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that the Company will host its fiscal fourth quarter and 2017 year-end financial results conference call on Wednesday, October 25th at 1:15 PM PT/4:15 PM ET.

To access the audio broadcast, please dial (877) 731- 1960 and enter the conference ID number: 86520374. An archived version of the presentation will be available for 90 days on the “Investors” section of OncoSec’s website:

About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or “tavo”). In Phase 1 and 2 clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile, evidence of anti-tumor activity in the treatment of various solid tumors, and the potential to reach beyond the site of local treatment to initiate a systemic immune response. OncoSec’s lead program, ImmunoPulse IL-12, is currently in clinical development for metastatic melanoma and triple-negative breast cancer. The program’s current focus is on the significant unmet medical need in patients with melanoma who are refractory or have relapsed on anti-PD-1 therapies. In addition to tavo, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse platform. For more information, please visit


Investor Relations 
OncoSec Medical Incorporated

Media Relations 
OncoSec Medical Incorporated

OncoSec Medical, Inc. Logo. Please visit for more information. (PRNewsFoto/OncoSec Medical, Inc.) (PRNewsfoto/OncoSec Medical Incorporated)


View original content with multimedia:

SOURCE OncoSec Medical Incorporated